Invesco Biotechnology & Genome ETF (PBE) Covered Calls

The Invesco Biotechnology & Genome ETF is an exchange-traded fund that tracks the Dynamic Biotech & Genome Intellidex Index. The fund provides targeted exposure to United States companies engaged in the research, development, and manufacture of various biotechnological products and services. It utilizes a quantitative selection process to identify stocks with strong capital appreciation potential based on price momentum, earnings growth, and management action within the genomic space.

You can sell covered calls on Invesco Biotechnology & Genome ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PBE (prices last updated Mon 12:05 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

The Invesco Biotechnology & Genome ETF (PBE) is a specialized investment vehicle that focuses on the intersection of biological science and technological innovation. The fund tracks an "Intellidex" index, which uses a proprietary methodology to select 30 U.S. biotechnology and genome companies. These firms are primarily involved in genetic engineering, molecular biology, and the development of novel therapies for complex diseases. Unlike broad healthcare funds, this ETF specifically targets the high-growth segments of the industry responsible for breakthrough medical research.

The portfolio includes a mix of established biopharmaceutical leaders and mid-sized innovators. Key holdings often feature companies like Gilead Sciences, Amgen, and Regeneron Pharmaceuticals. Additionally, the fund provides exposure to life sciences tools and services through holdings like Illumina, which is a leader in DNA sequencing. This concentrated approach ensures that the fund reflects the performance of companies that benefit significantly from scientific advancements in genomics and cellular research.

Competitive Landscape

The biotechnology ETF market is highly competitive, with several major funds vying for investor capital. PBE's most direct competitors include the iShares Biotechnology ETF, which tracks a much broader index of hundreds of names, and the SPDR S&P Biotech ETF, which utilizes an equal-weighted approach to capture the performance of smaller, more volatile biotech firms. These funds offer different risk profiles depending on their weighting schemes and the number of stocks held.

Other notable competitors in the space include the First Trust NYSE Arca Biotechnology Index Fund, which also uses a modified equal-weighted methodology for a fixed group of stocks. Investors often compare PBE to these alternatives based on expense ratios, liquidity, and the specific exposure to the "genome" sub-sector. Because PBE is optionable, it is frequently used by sophisticated traders to hedge against sector-specific volatility or to implement bullish strategies during periods of rapid medical innovation or heavy merger and acquisition activity.

Strategic Outlook and Innovation

The strategic framework for the fund is built on the premise that the biotech sector is entering a new era of productivity driven by artificial intelligence and high-throughput screening. Innovation is increasingly centered on personalized medicine, where treatments are tailored to the genetic makeup of individual patients. This shift is expected to accelerate the drug discovery process and improve the success rates of clinical trials. The fund is positioned to capture this trend by holding companies that are at the forefront of gene editing and synthetic biology.

Looking ahead, the fund focuses on the long-term thematic growth of global healthcare spending and the increasing demand for advanced treatments for age-related illnesses. The quantitative nature of the underlying index allows the fund to adapt to changing market dynamics by rotating into companies with the strongest fundamental momentum. By prioritizing firms with robust pipelines and proven management teams, the strategy aims to navigate the high-risk nature of clinical development while participating in the substantial upside potential of the next generation of life-saving medical breakthroughs.

Want more examples? PBD Covered Calls | PBF Covered Calls